PRESS RELEASES

Date	Title
Jan 13, 2014	Ardelyx Receives $15 Million Milestone as Part of Ongoing Tenapanor Collaboration with AstraZeneca
Oct 8, 2012	AstraZeneca and Ardelyx Announce Worldwide Licensing Deal For NHE3 Inhibitor Programme For Complications Of Renal Disease, Including Diabetes-Induced Renal Disease.
May 24, 2012	Ardelyx will present at the 22nd European Meeting on Hypertension and Cardiovascular Protection in London (UK) April 26-29, 2012
Apr 1, 2012	"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
Aug 31, 2011	Ardelyx Appoints Mark Kaufmann to Chief Business Officer
Aug 31, 2011	Ardelyx, Inc. Closes $30M Series B Financing

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Boston Area
200 West Street, 4th Floor
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com